Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Bilateral Refractive Amblyopia Treatment Study
This study has been completed.
Sponsored by: National Eye Institute (NEI)
Information provided by: National Eye Institute (NEI)
ClinicalTrials.gov Identifier: NCT00305955
  Purpose

The purpose of this study will be to:

  • Determine the amount of visual acuity improvement with treatment of presumed bilateral refractive amblyopia
  • Determine the time course of visual acuity improvement with treatment

Condition Intervention Phase
Bilateral Refractive Amblyopia
Device: Spectacles
Phase III

U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Bilateral Refractive Amblyopia Treatment Study

Further study details as provided by National Eye Institute (NEI):

Primary Outcome Measures:
  • Visual acuity of 20/25 or better in both eyes

Enrollment: 113
Study Start Date: August 2004
Study Completion Date: July 2006
Detailed Description:

There is a paucity of literature on bilateral amblyopia that is due to a substantial amount of refractive error (hypermetropia or astigmatism), and it is limited principally to review articles and case reports. The incidence is not known, but in one study, 4 of 830 (0.5%) children examined at the time of entry into school had bilateral amblyopia. Schoenleber et al performed a retrospective review of office records and identified 184 children with > +4.00 diopters of hypermetropia in both eyes, 12 of whom (6.5%) had bilateral amblyopia of 20/50 or worse. Ten of the 12 children (83%) improved to 20/40 or better in both eyes over a mean follow-up time of 22 months. Werner and Scott reported 6 cases of bilateral hypermetropic amblyopia with a spherical equivalent of at least +5.00 D and an initial visual acuity of 20/40 or worse in both eyes. All 5 patients with follow up improved with glasses alone, and 2 of these 5 had a most recent visual acuity worse than 20/40 in one eye with follow-up less than one year. Cavazos et al identified 218 eyes with hyperopia > +5.00 D or astigmatism >+2.00 D. Of these, 82 (38%) of the dominant eyes had an initial corrected visual acuity less than 20/25. Most improved to > 20/25, but many patients were lost to follow-up. In ongoing studies, bilateral refractive amblyopia is being evaluated in Native Americans.

  1. Patients will be enrolled who have bilateral refractive error with hyperopia >+4.00 D and/or astigmatism >2.00 D and have visual acuity in each eye, measured using best correction derived from cycloplegic refraction, meeting the following criteria:

    • Using E-ETDRS testing for patients age 7 to <11 years: visual acuity 20 to 70 letters (20/40 to 20/400)
    • Using ATS HOTV testing for patients age 3 to <7 years visual acuity 20/50 to 20/400
  2. Enrolled patients will be prescribed spectacles, which will be paid for by the study.
  3. The patient will return for a Spectacle Baseline visit within 30 days, at which time the spectacles will be placed on the patient for the first time and binocular and monocular visual acuities will be measured.

    • Patients whose monocular acuity at the Spectacle Baseline Visit is 20/25 or better in both eyes will end the study
    • Patients whose monocular acuity at the Spectacle Baseline Visit is worse than 20/25 in at least one eye will begin a one-year period of study follow up
  4. Follow-up visits are required at 5±:1 week, 13±:2 weeks, 26±:4 weeks, and 52±:4 weeks.

    • If at any follow-up visit a patient's monocular acuity is 20/25 or better in both eyes, the patient should return for the 52-week visit only and may skip the interim follow-up visits.

Sample size: The study plans to enroll 100 patients. At least 50 patients will be enrolled who have an interocular difference of less than 3 lines by ATS HOTV or less than 15 letters by E-ETDRS at the Spectacle Baseline visit.

  Eligibility

Ages Eligible for Study:   3 Years to 10 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 3 to <11 years
  • Able to perform single-surrounded single optotype visual acuity using the ATS HOTV protocol for children 3 to <7 years old and using the E-ETDRS protocol for children 7 to <11 years old
  • Monocular visual acuity in each eye, measured using trial frames or phoropter with best correction derived from cycloplegic refraction, meeting the following criteria:
  • Using E-ETDRS testing for patients age 7 to <11 years: visual acuity 20 to 70 letters (20/40 to 20/400)
  • Using ATS HOTV testing for patients age 3 to <7 years acuity 20/50 to 20/400
  • Refractive error that meets at least one of the following criteria in each eye:
  • Spherical equivalent >+4.00 D
  • Astigmatism >2.00 D
  • Investigator believes that the patient's reduced visual acuity is due to bilateral, refractive amblyopia
  • Investigator not planning to prescribe occlusion, patching or any other amblyopia treatment other than spectacles at this time
  • Cycloplegic refraction and ocular examination within 2 months prior to enrollment

Exclusion Criteria:

  • Myopia greater than -6.00 D of spherical power in plus cylinder form
  • Ocular cause for decreased acuity in either eye; nystagmus per se will not exclude a patient from the study
  • Refractive correction (spectacles or contact lenses) in past three months and no more than one month of refractive correction ever
  • Prior treatment for amblyopia (other than the refractive correction permitted in previous exclusion criteria)
  • Prior intraocular or refractive surgery
  • Use of contact lenses during the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00305955

Locations
United States, North Carolina
Duke University Eye Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Investigators
Principal Investigator: David K. Wallace, M.D. Duke University Eye Center
  More Information

Pedig Public website  This link exits the ClinicalTrials.gov site
NEI Clinical Studies Database  This link exits the ClinicalTrials.gov site

Publications of Results:
Study ID Numbers: NEI-101
Study First Received: March 20, 2006
Last Updated: November 13, 2007
ClinicalTrials.gov Identifier: NCT00305955  
Health Authority: United States: Federal Government

Keywords provided by National Eye Institute (NEI):
amblyopia
bilateral amblyopia
refractive error

Study placed in the following topic categories:
Signs and Symptoms
Sensation Disorders
Vision Disorders
Amblyopia
Eye Diseases
Neurologic Manifestations
Central Nervous System Diseases
Brain Diseases
Refractive Errors

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009